MedPath

CCP Cancer UK Study. Companion study to educate and inform practice and guidelines regarding COVID-19 infection in cancer patients

Not Applicable
Completed
Conditions
Cancer, COVID-19 (SARS-CoV-2 infection)
Cancer
Registration Number
ISRCTN15019599
Lead Sponsor
Clatterbridge Cancer Centre NHS Foundation Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
5000
Inclusion Criteria

Patients with proven COVID-19 and a diagnosis of cancer who are enrolled into any tier of the Principal CCP-UK protocol

Exclusion Criteria

None in addition to those specified in the Principal CCP-UK protocol:

Exclusion criteria specified in CCP-UK Protocol:
1. Confirmed diagnosis of a pathogen unrelated to the objectives of this study and no indication or likelihood of co-infection with a relevant pathogen
2. Refusal by participant, parent or appropriate representative

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome measure as of 30/04/2024:<br>Measured at the end of the study:<br>1. Determine the mortality rate in patients with cancer and COVID-19, using data from the CCP-UK study and linked data<br>2. Identify factors associated with the poor outcomes in patients with cancer and COVID-19, using data from the CCP-UK study and linked data<br><br><br><br>Previous primary outcome measure:<br>Measured at the end of the study:<br>1. Mortality rate in patients with cancer and COVID-19, using data from the CCP-UK study and linked data <br>2. Factors associated with the poor outcomes in patients with cancer and COVID-19, using data from the CCP-UK study and linked data
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath